355 related articles for article (PubMed ID: 17499324)
1. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
[TBL] [Abstract][Full Text] [Related]
2. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
Kitchin KT; Conolly R
Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic modeling of arsenic in the mouse.
Gentry PR; Covington TR; Mann S; Shipp AM; Yager JW; Clewell HJ
J Toxicol Environ Health A; 2004 Jan; 67(1):43-71. PubMed ID: 14668111
[TBL] [Abstract][Full Text] [Related]
4. How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review.
Kenyon EM; Klimecki WT; El-Masri H; Conolly RB; Clewell HJ; Beck BD
Toxicol Appl Pharmacol; 2008 Nov; 232(3):359-68. PubMed ID: 18687352
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment of arsenic-induced internal cancer at long-term low dose exposure.
Liao CM; Shen HH; Chen CL; Hsu LI; Lin TL; Chen SC; Chen CJ
J Hazard Mater; 2009 Jun; 165(1-3):652-63. PubMed ID: 19062162
[TBL] [Abstract][Full Text] [Related]
6. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?
Snow ET; Sykora P; Durham TR; Klein CB
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):557-64. PubMed ID: 15996700
[TBL] [Abstract][Full Text] [Related]
7. Use of mode of action data to inform a dose-response assessment for bladder cancer following exposure to inorganic arsenic.
Gentry PR; Yager JW; Clewell RA; Clewell HJ
Toxicol In Vitro; 2014 Oct; 28(7):1196-205. PubMed ID: 24937311
[TBL] [Abstract][Full Text] [Related]
8. Arsenic-induced bladder cancer in an animal model.
Cohen SM; Ohnishi T; Arnold LL; Le XC
Toxicol Appl Pharmacol; 2007 Aug; 222(3):258-63. PubMed ID: 17109909
[TBL] [Abstract][Full Text] [Related]
9. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water.
Kenyon EM; Hughes MF; Adair BM; Highfill JH; Crecelius EA; Clewell HJ; Yager JW
Toxicol Appl Pharmacol; 2008 Nov; 232(3):448-55. PubMed ID: 18706920
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the carcinogenicity of inorganic arsenic.
Cohen SM; Arnold LL; Beck BD; Lewis AS; Eldan M
Crit Rev Toxicol; 2013 Oct; 43(9):711-52. PubMed ID: 24040994
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
12. Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity.
Gentry PR; McDonald TB; Sullivan DE; Shipp AM; Yager JW; Clewell HJ
Environ Mol Mutagen; 2010 Jan; 51(1):1-14. PubMed ID: 19551812
[TBL] [Abstract][Full Text] [Related]
13. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
[TBL] [Abstract][Full Text] [Related]
14. Research approaches to address uncertainties in the risk assessment of arsenic in drinking water.
Hughes MF; Kenyon EM; Kitchin KT
Toxicol Appl Pharmacol; 2007 Aug; 222(3):399-404. PubMed ID: 17379267
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites.
Kitchin KT
Toxicol Appl Pharmacol; 2001 May; 172(3):249-61. PubMed ID: 11312654
[TBL] [Abstract][Full Text] [Related]
16. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
[TBL] [Abstract][Full Text] [Related]
17. A human PBPK/PD model to assess arsenic exposure risk through farmed tilapia consumption.
Ling MP; Liao CM
Bull Environ Contam Toxicol; 2009 Jul; 83(1):108-14. PubMed ID: 19452117
[TBL] [Abstract][Full Text] [Related]
18. Implications of arsenic genotoxicity for dose response of carcinogenic effects.
Rudel R; Slayton TM; Beck BD
Regul Toxicol Pharmacol; 1996 Apr; 23(2):87-105. PubMed ID: 8661328
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of responses to dimethylarsinic acid in female F344 rat urothelium.
Sen B; Wang A; Hester SD; Robertson JL; Wolf DC
Toxicology; 2005 Nov; 215(3):214-26. PubMed ID: 16122865
[TBL] [Abstract][Full Text] [Related]
20. Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects.
Schuhmacher-Wolz U; Dieter HH; Klein D; Schneider K
Crit Rev Toxicol; 2009; 39(4):271-98. PubMed ID: 19235533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
